enVVeno Medical (NVNO) Fundamental Analysis: Revenue, Earnings & Valuation

0.86 / 10

Underperform

Fundamental analysis rates NVNO as Underperform with a 0.9/10 score. Revenue‑MV and cash‑MV are negative, ROA and profit margins are deeply negative, and only Profit‑MV shows modest strength. Overall, the company’s financial health appears weak.

Analysis Checks(1/10)

Revenue-MV

Value-0.28

Score0/3

Weight19.37%

1M Return-4.18%

ROA (%)

Value-52.26

Score1/3

Weight4.04%

1M Return-0.82%

Net cash flow from operating activities / Operating revenue (%)

Value-982.50

Score0/3

Weight21.45%

1M Return-6.63%

Profit-MV

Value0.40

Score2/3

Weight-18.30%

1M Return3.09%

Annualized net profit margin on total assets (%)

Value-52.26

Score1/3

Weight4.04%

1M Return-0.82%

EBIT / Total operating revenue (%)

Value-1049.47

Score0/3

Weight21.45%

1M Return-5.19%

Asset-MV

Value-0.49

Score1/3

Weight-1.95%

1M Return0.38%

Net profit / Total operating revenue (%)

Value-654.10

Score0/3

Weight21.84%

1M Return-6.68%

Cash-MV

Value-0.09

Score1/3

Weight17.35%

1M Return-4.16%

Net profit / Total profit (%)

Value100.00

Score1/3

Weight10.71%

1M Return-2.39%

Is NVNO undervalued or overvalued?

NVNO scores 0.86/10 on fundamentals and holds a Premium valuation at present. Backed by its -56.21% ROE, 0.00% net margin, -0.35 P/E ratio, 0.25 P/B ratio, and 25.76% earnings growth, these metrics solidify its Underperform investment rating.